The US FDA has warned Taipei, Taiwan-based drugmaker Vida International over GMP violations following an inspection of the company’s Taoyuan City facility. As a result of the observations made during the inspection, the FDA placed Vida on import alert in March. In the warning letter, the FDA cites Vida for failing to conduct necessary batch testing for one of its products before release. The FDA also says the firm failed to test incoming raw materials, including active ingredients, to determine their identity and whether they conform to written specifications before use. According to the FDA, Vida also prepared an inaccurate batch record for a lot of one of its drugs. Learn More